Evidence map›Paper›PMID 41736789›Full record

ArticleFrontiers in cellular and infection microbiology2026

Solithromycin mitigates

Koki Fukushima, Naoki Iwanaga, Nobuyuki Ashizawa, Kazuaki Takeda, Tatsuro Hirayama, Masataka Yoshida, Shotaro Ide, Takahiro Takazono, Kosuke Kosai, Noriho Sakamoto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Journal of bacteriology · 2026
    Review
  2. Commentary: Solithromycin mitigatesFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Koki FukushimaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Naoki IwanagaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nobuyuki AshizawaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Kazuaki TakedaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Tatsuro HirayamaDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masataka YoshidaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Shotaro IdeInfectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Kosuke KosaiDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Noriho SakamotoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Mariko NaitoDepartment of Microbiology and Oral Infection, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ventilator-associated pneumonia (VAP) is a fatal intensive care infection. VAP caused by methicillin-resistant Methods: BALB/cCrSlc mice received MRSA and Results: Conclusion: SOL protects by activating alveolar macrophages and promoting TNF-related responses, suggesting a novel immunomodulatory role for SOL in host defense against exacerbation of MRSA-VAP by

Indexed as

Anti-Bacterial AgentsBacteroidaceae InfectionsMacrolidesMacrophages, AlveolarMethicillin-Resistant Staphylococcus aureusPneumonia, Ventilator-AssociatedPrevotella intermediaTriazolesAnimalsClarithromycinDisease Models, AnimalLungMiceMice, Inbred BALB CPhagocytosisStaphylococcal InfectionsAnti-Bacterial AgentsClarithromycinMacrolidessolithromycinTriazolesalveolar macrophagesimmunomodulationmethicillin-resistant Staphylococcus aureusPrevotella intermediaRNAsequencingsolithromycinventilator-associated pneumonia

Identifiers

PMID41736789
PMCPMC12926392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.